ScholarIQanswers from OpenAlex & ORCID
Denise A. Yardley
ResearcherPublications, citations & collaboration network
Denise A. Yardley is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Denise A. Yardley have?
ScholarIQindexed works
Denise A. Yardley has 562 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Denise A. Yardley have?
ScholarIQcitation count
Denise A. Yardley has 27,323 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Denise A. Yardley?
ScholarIQh-index
Denise A. Yardley has an h-index of 68 in OpenAlex.
What is the i10-index of Denise A. Yardley?
ScholarIQi10-index
Denise A. Yardley has an i10-index of 191 in OpenAlex.
What is the ORCID of Denise A. Yardley?
ScholarIQorcid
The ORCID for Denise A. Yardley is on the source record.
What is the OpenAlex record for Denise A. Yardley?
ScholarIQopenalex
The OpenAlex for Denise A. Yardley is on the source record.
What are the most-cited papers on Denise A. Yardley?
ScholarIQmost cited works
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Chan, Xian Zhou, S. Phan, Joyce O’Shaughnessy
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Beth Overmoyer, Ann H. Partridge, Hao Guo, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Eric P. Winer
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Dièras, Debra A. Patt, Hans Wildiers, Clifford A. Hudis, Joyce O’Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E. Krop, Ingrid A. Mayer, Vinod Ganju, Maura N. Dickler, Stephen Johnston, Serafín Morales, Denise A. Yardley, Bohuslav Melichar, Andres Forero‐Torres, Soo Chin Lee, Richard de Boer, Katarína Petráková, Susanne Vallentin, Edith A. Perez, Martine Piccart, Matthew J. Ellis, Eric P. Winer, Steven Gendreau, Mika K. Derynck, Mark R. Lackner, Gallia G. Levy, Jiaheng Qiu, Jing He, Peter Schmid